Increased taurine in pre-weaned juvenile mdx mice greatly reduces the acute onset of myofibre necrosis and dystropathology and prevents inflammation.
BACKGROUND
The mdx mouse model for the fatal muscle wasting disease Duchenne Muscular Dystrophy (DMD) shows a very mild pathology once growth has ceased, with low levels of myofibre necrosis in adults. However, from about 3 weeks of post-natal age, muscles of juvenile mdx mice undergo an acute bout of severe necrosis and inflammation: this subsequently decreases and stabilises to lower adult levels by about 6 weeks of age. Prior to the onset of this severe dystropathology, we have shown that mdx mice are deficient in the amino acid taurine (potentially due to weaning), and we propose that this exacerbates myofibre necrosis and inflammation in juvenile mdx mice.


OBJECTIVE
The purpose of this study was to increase taurine availability to pre-weaned juvenile mdx mice (from 14 days of age), to evaluate the impact on levels of myofibre necrosis and inflammation (at 22 days) during the acute period of severe dystropathology.


RESULTS
Untreated 22 day old mdx muscle was not deficient in taurine, with similar levels to normal C57 control muscle. However taurine treatment, which increased the taurine content of young dystrophic muscle (by 40%), greatly reduced myofibre necrosis (by 75%) and prevented significant increases in 3 markers of inflammation.


CONCLUSIONS
Taurine was very effective at preventing the acute phase of muscle damage that normally results in myofibre necrosis and inflammation in juvenile mdx mice, supporting continued research into the use of taurine as a therapeutic intervention for protecting growing muscles of young DMD boys.
The University of Western Australia.
Jessica R
JR
Terrill
School of Anatomy and Human Biology, the University of Western Australia, Perth, Australia.
Miranda D
MD
Grounds
School of Chemistry and Biochemistry, The University of Western Australia, Perth, Western Australia.
Peter G
PG
Arthur
Early Hum Dev. 1978 Apr;2(1):1-13
102507
Cell Mol Life Sci. 2008 Jun;65(11):1621-5
18327663
Lancet. 2002 Feb 23;359(9307):687-95
11879882
Int J Biochem Cell Biol. 2015 Sep;66:141-8
26239309
Am J Physiol Regul Integr Comp Physiol. 2000 Oct;279(4):R1165-70
11003979
FASEB J. 2004 Apr;18(6):676-82
15054089
Free Radic Biol Med. 2000 Sep 1;29(5):403-9
11020661
J Physiol. 2016 Jun 1;594(11):3095-110
26659826
FASEB J. 2004 Mar;18(3):577-9
14734644
Int J Biochem Cell Biol. 2013 Sep;45(9):2097-108
23892094
Physiol Rev. 2016 Jan;96(1):253-305
26676145
Circ Res. 2004 Apr 30;94(8):1023-31
15117830
Pediatr Rev. 2006 Mar;27(3):83-8
16510548
Bioessays. 2011 Jun;33(6):458-68
21500235
Lancet Neurol. 2010 Jan;9(1):77-93
19945913
J Transl Med. 2015 Jul 25;13:243
26208967
Neurochem Res. 2004 Jan;29(1):135-42
14992272
Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003725
18254031
Toxicology. 2002 Dec 27;181-182:223-7
12505315
Acta Myol. 2012 May;31(1):40-7
22655516
J Dairy Sci. 1972 Oct;55(10):1502-5
5077616
J Physiol. 2002 Jan 1;538(Pt 1):185-94
11773327
J Histochem Cytochem. 2001 Aug;49(8):989-1001
11457927
Am J Physiol Regul Integr Comp Physiol. 2005 Feb;288(2):R345-53
15637171
Physiol Rev. 1992 Jan;72(1):101-63
1731369
Amino Acids. 2014 Jan;46(1):7-20
22810731
J Pharmacol Exp Ther. 2003 Jan;304(1):453-63
12490622
Methods Enzymol. 2007;428:439-58
17875433
Biomed Res Int. 2014;2014:965631
24877152
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3710-4
8475120
Neuropathol Appl Neurobiol. 2011 Apr;37(3):243-56
20618838
Nat Methods. 2012 Jul;9(7):671-5
22930834
J Neurol Sci. 1993 Nov;119(2):169-79
8277331
Br J Pharmacol. 2001 Mar;132(5):1047-54
11226135
Int J Biochem Cell Biol. 2007;39(3):469-77
17137828
Amino Acids. 2006 Oct;31(3):273-8
16583307